Eflapegrastim, a novel long-acting granulocyte-colony stimulating factor: Integrated safety results in patients with early-stage breast cancer treated with TC chemotherapy

Authors
Category Primary study
JournalCancer Research
Year 2020
This article has no abstract
Epistemonikos ID: 9275fe6aeb5118ecc812293bc19de3a577419a04
First added on: Feb 11, 2025